Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.37 |
| ▸ | CA7 | P43166 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.37 |
| ▸ | NOS3 | P29474 | 3/20 | 0.35 |
| ▸ | NOS1 | P29475 | 3/20 | 0.35 |
| ▸ | NOS2 | P35228 | 3/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13869052 | 1.00 | SMN1; SMN2 (0.41) | SMN1; SMN2ADAM17MMECA12CA14 | |
| SCHEMBL762169 | 1.00 | SMN1; SMN2 (0.41) | SMN1; SMN2ADAM17MMECA12CA14 | |
| SCHEMBL15060855 | 0.82 | CA1 (0.36) | SMN1; SMN2ADAM17MMETAS1R3TAS1R1 | |
| SCHEMBL14748186 | 0.81 | TSHR (0.45) | SMN1; SMN2CA7MMP1MMP2MMP3 | |
| SCHEMBL13537881 | 0.81 | MMP8 (0.41) | MMP1MMP2MMP3 | |
| SCHEMBL14770005 | 0.81 | TSHR (0.36) | ADAM17CA7MMP1MMP2MMP3 | |
| SCHEMBL13946436 | 0.80 | TSHR (0.34) | ADAM17CA12CA9TAS1R3TAS1R1 | |
| SCHEMBL10069154 | 0.78 | HCAR2 (0.37) | TAS1R3TAS1R1MMP1MMP2MMP3 | |
| SCHEMBL13690140 | 0.78 | TSHR (0.36) | MMP1MMP2MMP3 | |
| SCHEMBL13690831 | 0.77 | CA1 (0.47) | SMN1; SMN2CA12CA14CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230130685-A1 | Binder Composition for Secondary Battery, Negative Electrode for Secondary Battery Including the Same, and Lithium Secondary Battery Including the Same | SK ON CO., LTD. (KR) | 2023-04-27 | — | — | US | disclosed |
| US-8138177-B2 | Benzimidazolone derivatives as CB2 receptor ligands | PFIZER INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20090181957-A1 | BENZIMIDAZOLONE DERIVATIVES AS CB2 RECEPTOR LIGANDS | ANDO KAZUO | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181957-A1 | BENZIMIDAZOLONE DERIVATIVES AS CB2 RECEPTOR LIGANDS | TRPV1, CNR1, CNR2 | SMN1; SMN2 1260/4885ADAM17 4126/4885MME 4157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.